Current Report Filing (8-k)
April 21 2020 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of report
(Date of earliest event reported): April 21, 2020
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State or Other Jurisdiction
of Incorporation)
|
001-31918
(Commission
File Number)
|
04-3072298
(I.R.S Employer
Identification No.)
|
|
|
|
505 Eagleview Blvd., Suite 212
Exton, Pennsylvania
(Address of Principal Executive Offices)
|
|
19341
(Zip Code)
|
Registrant’s telephone number, including
area code: (484) 348-1600
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
IDRA
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
|
Item 7.01
|
Regulation FD Disclosure.
|
On April 21, 2020, Idera Pharmaceuticals,
Inc. (the “Company,” “we,” “us,” and “our”) issued a press release announcing final
topline data from the ILLUMINATE-204 trial investigating intratumoral tilsotolimod. A copy of the press release is attached to
this Current Report on Form 8-K as Exhibit 99.1.
The Company is furnishing the information
in this Item 7.01 and the related Exhibit 99.1 filed herewith to comply with Regulation FD. Such information shall not
be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into
any of the Company’s filings under the Securities Act of 1933, as amended, whether made before or after the date hereof and
regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference
in such a filing. This Item 7.01 will not be deemed an admission as to the materiality of any information herein (including Exhibit
99.1) that is required to be disclosed solely by Regulation FD.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDERA PHARMACEUTICALS,
INC.
|
|
|
|
By:
|
/s/ Bryant D. Lim
|
|
|
Bryant D. Lim
|
|
|
Senior V.P., General Counsel
|
Dated: April 21, 2020
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024